Mariner’s VanEck Biotech ETF BBH Stock Holding History

Mariner’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-300	Closed	-$35K	–	581
2016 Q3	$35K	Buy	+300	New	+$34.2K	﹤0.01%	666

Other funds holding BBH

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Mariner's BBH Position: Q4 2016 in Review

Mariner sold out of VanEck Biotech ETF (BBH) in Q4 2016, closing a stake of 300 shares — an estimated $35K sold.

Mariner first reported a position in BBH in Q3 2016 and held it in 1 quarter. The position peaked at $35K in Q3 2016. 86 funds tracked by Wall St. Rank hold BBH as of Q4 2016.

Mariner reported no remaining VanEck Biotech ETF position as of Q4 2016 after selling out during the quarter.
Mariner sold 300 VanEck Biotech ETF shares in Q4 2016, an estimated $35K.
Mariner first reported a position in VanEck Biotech ETF in Q3 2016 and held it in 1 quarter.
Mariner's VanEck Biotech ETF position peaked at $35K in Q3 2016.
86 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2016.

Based on Mariner's 13F filing for Q4 2016, filed 14 Feb 2017.